VIVUS, Inc. (NASDAQ:VVUS)
CAPS Rating:
A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.
RSS Headlines
Fool UK
Recs
Inflated by ARNA approval, will crash to actual value if rejected or with restrictive label. Management has a black eye from handling of FDA announcement.